The Cannes Convention, in the name of team spirit

The Convention of IBSA Pharma, the Group’s French subsidiary, was held in Cannes from March 28 to April 1, 2022. 250 People from IBSA gathered to share activities and projects, to do training and – above all – to do teamwork.

Antonio Melli, IBSA Group Vice President, said: “Although IBSA had been present with its products on the French market for over thirty years, through the collaboration with its own distributor, the launch of its own subsidiary, IBSA Pharma, headquartered in Sophia Antipolis, opens an era of collaboration and further expansion in an important market like the French one. It was really exciting and a source of great pride to see the enthusiasm and passion of this convention. We are pleased to be at the side of our French colleagues in pursuing increasingly challenging market objectives, aimed at driving IBSA Pharma towards a bright future”.

The route taken by the French subsidiary, the corporate projects that concern the entire Group, the results achieved and the goals to be attained: the week’s agenda was really rich. There were moments of training on new marketing campaigns and new launches, contributions by experts in the leading laboratory therapeutic areas, training on the most recent regulations, in addition to plenary meetings in which the Department Heads and the Marketing and Sales Managers presented a retrospective on 2021 and the program planned for 2022. There were also moments of interaction between associates from IBSA’s Antibes headquarters and the Swiss and Italian leadership, as well as a gala evening to conclude the week.

“This convention was the first occasion, since the birth of IBSA Pharma, where we could bring together all our people and welcome them here, in France”, announced Fabrice Jover, General Manager of IBSA Pharma. “Events like this allow us to experience what it means to be part of one big team, exchanging the positive energy necessary to work in harmony”.

THE IMPORTANCE OF IBSA PHARMA AND THE FRENCH MARKET

For the new French subsidiary, the decision to meet in Cannes was an opportunity to welcome the entire team and tell them about the beginning of the new journey.

“Even after such a short time since the birth of IBSA Pharma, we are realising how much we have already achieved. We know we have a complex but incredibly challenging path ahead of us, given the importance of the French market within the Group’s strategies”, explained Massimiliano Licenziati, Chairman of IBSA Pharma. “We are honoured to have met here our colleagues and collaborators, because success is only possible with mutual support and a constant exchange with the Headquarters and all IBSA subsidiaries”.

LOOKING AHEAD: IBSA SAILING INTO THE FUTURE. TOGETHER

Once again, it is by looking ahead that IBSA launched the new project Sailing into the Future. Together, a sporting venture that also metaphorically represents the company’s vision, committed to the constant challenge of going beyond care, for the actual well-being of the Person.

Talking about this important project during the Cannes Convention was skipper Alberto Bona, who, with the support of IBSA, will take part in several international solo regattas (including the prestigious Route du Ruhm – Destination Guadalupe) on a Class40 boat, currently under construction. The Route du Rhum will see Alberto Bona set sail from Saint-Malo (Brittany) in November 2022, eventually landing at Pointe-à-Pitre, on the island of Guadeloupe, in the French Antilles.

The project Sailing into the Future. Together was launched in March this year, and will run for three years. But the initiative – which goes beyond solo regattas – will allow IBSA to promote inclusive sailing activities, by supporting sailing centres through the provision of boats designed for people with disabilities. Among the subsidiaries involved, IBSA Headquarters, IBSA Farmaceutici, IBSA Switzerland and IBSA Pharma are at the forefront of the project, and will be the main actors of future events, regatta stages and broader sustainability-related initiatives.